Skip to main content

Atypical Parkinsonism clinical trials at University of California Health

2 in progress, 0 open to eligible people

Showing trials for
  • AMX0035 and Progressive Supranuclear Palsy

    Sorry, in progress, not accepting new patients

    A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.

    at UCSF

  • Parkinson's and Zoledronic Acid

    Sorry, in progress, not accepting new patients

    This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    at UC Davis UC Irvine UCLA UCSF

Last updated: